Tags Archives: vasoplegic shock

thumbnail
0 comment

The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock

Abstract Background Vasoplegic syndrome is associated with high mortality. Methylene blue (MB) is a guanylate cyclase inhibitor that ameliorates this re-distributive type of shock. This study aims to investigate the..

Read More
thumbnail
0 comment

Hydroxocobalamin Versus Methylene Blue for Treatment of Vasoplegic Shock Following Cardiopulmonary Bypass: A Systematic Review and Meta-analysis

Abstract Objectives To summarize the evidence of the hemodynamic effects and vasopressor requirements of adult cardiac surgery patients with vasoplegic shock treated with hydroxocobalamin or methylene blue. Design Systematic review..

Read More
thumbnail
0 comment

Clinical Medicine Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement

Abstract A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still..

Read More
thumbnail
0 comment

Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement

Abstract A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still..

Read More
thumbnail
0 comment

Hydroxocobalamin Versus Methylene Blue for the Treatment of Vasoplegic Shock Associated With Cardiopulmonary Bypass

Abstract Objectives To compare changes in vasopressor requirements and hemodynamic responses after hydroxocobalamin or methylene blue administration for vasoplegic shock (VS). Design Retrospective cohort analysis. Setting Single-center, academic medical center...

Read More
thumbnail
0 comment

CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol…

Abstract Objectives Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy..

Read More
thumbnail
0 comment

Methylene Blue for Vasoplegia During Extracorporeal Membrane Oxygenation Support

Abstract Objective The treatment of refractory vasodilatory shock in patients undergoing  (ECMO) is an area in which there is minimal literature. Based on previous literature, the authors hypothesized that at least..

Read More
thumbnail
0 comment

Vasopressor Therapy in Cardiac Surgery—An Experts’ Consensus Statement

Abstract Hemodynamic conditions with reduced  commonly are observed in patients undergoing cardiac surgery and may range from moderate reductions in , as a side effect of general anesthetics, to a profound vasodilatory..

Read More
thumbnail
0 comment

Cardiovascular Consequences and Considerations of Coronavirus Infection – Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis

THE CURRENT pandemic owing to coronavirus disease 2019 (COVID-19) has been associated in about 10% to 15% of cases with severe clinical presentations that require admission to hospital.  In the..

Read More
thumbnail
0 comment

CytoSorb Therapy Intelligent Blood Purification for hemodynamic stabilization in vasoplegic shock

In these patients there is a high chance of success (shock reversal) possibly translating to survival benefits when the adsorber treatment is started in good time.   [pdf-embedder url="https://perfusfind.com/wp-content/uploads/2021/02/CytoSorb-Therapy_compressed.pdf" title="CytoSorb..

Read More